A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8
Open Access
- 1 November 2011
- journal article
- case report
- Published by Elsevier BV in Molecular Therapy
- Vol. 19 (11), 2084-2091
- https://doi.org/10.1038/mt.2011.108
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Preexisting Immunity and Low Expression in Primates Highlight Translational Challenges for Liver-directed AAV8-mediated Gene TherapyMolecular Therapy, 2010
- Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV VectorsHuman Gene Therapy, 2010
- AAV-1–mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cellsBlood, 2009
- Diverse IgG subclass responses to adeno‐associated virus infection and vector administrationJournal of Medical Virology, 2008
- Adeno-Associated Virus Vector Genomes Persist as Episomal Chromatin in Primate MuscleJournal of Virology, 2008
- Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapyBlood, 2006
- Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8Molecular Therapy, 2006
- Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID miceBlood, 2006
- HEPARIN‐INDUCED THROMBOCYTOPENIA WITH THROMBOSIS: SUCCESSFUL THREATMENT WITH PLASMA EXCHANGEBritish Journal of Haematology, 1998
- Neutralization of Epstein-Barr Virus by Nonimmune Human SerumJCI Insight, 1982